基本信息
views: 105
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Simon studied molecular biology at the University of Edinburgh and did his PhD at the University of Cambridge with Professor Steve Jackson (Gurdon Institute). He then conducted EMBO and HFSP funded postdoctoral fellowships at Harvard Medical School, Boston, with Prof. Nick Dyson (MGH Cancer Centre) and Prof. Marc Vidal (Dana Faber Cancer Institute). In 2002, he returned to the UK to establish the DNA Damage Response Laboratory at Cancer Research UK, London Research Institute, Clare Hall Laboratories. He is now a senior group leader at the Francis Crick Institute and holds honorary appointments at UCL, Kings College and Imperial. Simon's lab exploits the respective experimental strengths of C. elegans and mouse genetics, cell biology and biochemistry to study the mechanisms of DNA double strand break repair in mitotic and meiotic cells.
Over the years Simon's lab has discovered novel DNA repair genes and provided molecular insights into human diseases. As a result of his ground-breaking work, Simon has received a number of prestigious accolades for his work, notably election as a member of EMBO and to the Fellowship of the Academy of Medical Sciences. He has also been awarded the Colworth Medal, the European Association for Cancer Research (EACR) Young Investigator Award, the Eppendorf/Nature Award for Young European Investigators, the Royal Society Wolfson Research Merit award, the EMBO Gold Medal and the Paul Marks Prize for Cancer Research. He has also given numerous prize lectures, most notably the Royal Society Francis Crick Prize lecture and the Mendel Lecture. In 2016, Simon helped to establish Artios Pharma Ltd, where he functions as Vice President Science Strategy alongside his main role as Senior Group Leader at the Francis Crick Institute. Artios Pharma Ltd is building an innovative DNA Damage Response (DDR) target pipeline with the potential to transform cancer therapy. Artios are developing breakthrough cancer treatments that target DDR pathways to selectively kill cancer cells.
Research Interests
Papers共 208 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
crossref(2024)
Nature Geneticsno. 1 (2024): 12-13
NUCLEIC ACIDS RESEARCHno. 4 (2024): 1736-1752
Molecular Cellno. 11 (2024): 2203-2213.e5
Journal of visualized experiments : JoVE (2024)
Genes & developmentno. 7-8 (2024): 354-354
Natureno. 7970 (2023): 650-657
crossref(2023)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn